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Introduction 
 
There are 17 members in the KLF protein fam-
ily. Many of them have been shown to play a 
role in cancer [1]. Some of these transcription 
factors act as transcriptional activators, some 
act as transcriptional repressors and other 
members have a dual role in both activating 
and repressing gene expression. All of the KLF 
proteins share three highly conserved Cys2His2 
zinc finger motifs in DNA (CACCC GT-box or GC-
rich element) binding domain at their C-
terminus with diverse N-terminal regulatory ele-
ments [2].  
 
KLF8 possesses highly conserved zinc finger 
domains at its C-terminus that binds to the 
CACCC region of target gene promoters [3]. 
KLF8 was first reported as a transcriptional rep-
ressor of beta-globin gene expression [3]. It has 
subsequently been identified as a critical regu-
lator of cell proliferation, oncogenic transforma-
tion, epithelial to mesenchymal transition (EMT), 
tumor invasion and metastasis. Although con-
sidered widely expressed, KLF8 expression is 
barely detectable in most normal cell and tissue 
types, but highly increased in a number of hu-
man cancer types. Thus, KLF8 has emerged as 
an important cancer-regulating protein.  
The structure of KLF8 protein 
 
KLFs are named after homology with Krüppel 
protein of Drosophila melanogaster. KLF8 is 
present in most of the species. In human KLF8 
is located in the chromosome X [4]. Human 
KLF8 protein consists of 359 amino acid resi-
dues. It was first isolated from the K562 leuke-
mia cell line [5]. A typical transcription factor 
contains three essential domains for its activity, 
1) a nuclear localization signal to transport the 
protein into the nucleus, 2) a DNA binding do-
main to interact with promoter DNA and 3) a 
transcriptionally regulatory domain to regulate 
gene expression. The DNA binding domain is 
highly conserved in all KLF proteins. In some 
cases the Zinc finger domains also mediate 
protein-protein interaction.  
 
As depicted in Figure 1, KLF8 protein shares 
with KLF3 and KLF12 a C-terminal binding pro-
tein (CtBP) interacting domain in its N-terminus 
[3]. CtBP is a transcriptional co-repressor pro-
tein. The Pro-Val-Asp-Leu-Ser (PVDLS) motif (86-
90 aa) in KLF8 N-terminus is recognized by 
CtBP. KLF8 interaction with CtBP triggers KLF8 
transcriptional repression activity. Along with its 
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transcriptional repression activity, KLF8 also 
acts as a transcriptional activator [5, 6]. The 
glutamine residues Q118 and Q248 of KLF8 are 
essential for KLF8 transcriptional activation 
function [7]. The two putative classical nuclear 
localization signals (NLS) flanking the zinc finger 
domains do not regulate KLF8 nuclear localiza-
tion [8]. The post translational modifications 
such as sumoylation and acetylation of KLF8 do 
not appear to impact the nuclear localization of 
KLF8, either. The serine 165 (S165) and lysine 
171 (K171) residues of KLF8 are critical for its 
nuclear localization. The C-terminal zinc finger 
domains 1 and 2 bind to importin-beta, a pro-
tein which imports cytosolic proteins to the nu-
cleus. The exact role of the S165 and K171 
residues in regulating nuclear localization of 
KLF8 remains to be determined. However, it is 
speculated that PKC may phosphorylate KLF8 
at the S165 residue, facilitating the localization 
of the protein to the nucleus. Inhibition of PKC 
activity by specific PKC inhibitor decreases the 
nuclear localization of KLF8 [8]. These sites are 
also important for cellular function of KLF8 as 
KLF8 mutant without these regions failed to 
activate cyclin D1 expression compared to wild 
type KLF8 [8]. New DNA synthesis was also de-
creased in cells expressing these mutants. Poly 
(ADP-Ribose) Polymerase 1 (PARP-1) is an im-
portant protein involved in DNA repair, post 
translational modification known as PARylation, 
DNA transcription, chromatin modeling and can-
cer progression [9-11]. PARP-1 has been widely 
accepted as a therapeutic target for cancer 
treatment [11]. Recently PARP-1 has been iden-
tified as a protein interacting with the Zn finger 
motifs 1 and 2 of KLF8 [12]. This interaction 
helps stabilize KLF8 protein in the nucleus. In 
PARP-1 null cells KLF8 half-life is significantly 
reduced and the level of ubiquitinated KLF8 is 
significantly increased. KLF8 interaction with 
and PARylation by PARP-1 is critical for its nu-
clear localization. PARP-1 interaction prevents 
nuclear exporting protein CRM1 from binding to 
KLF8 and thus inhibits KLF8 export out of the 
nucleus. Inhibition of the interaction between 
KLF8 and PARP-1 leads to the cytoplasmic local-
ization of KLF8. It is believed to be caused by 
increased KLF8 transport by CRM1 to the cyto-
plasm where KLF8 is ubiquitinated and subse-
quently degraded presumably by proteasome 
[12]. Activation of cyclin D1 promoter by KLF8 
was significantly reduced when PARP-1 was 
knocked down or inhibited. KLF8 transcriptional 
activity can be restored by re-expressing PARP-1 
in PARP-1 null cells indicating that KLF8 interac-
tion with PARP-1 and PARylation in the nucleus 
are crucial for KLF8 transcriptional activity and 
cellular function [12] See Figure 1. 
 
The expression and modifications of KLF8  
 
Understanding the mechanisms behind the ele-
vated expression of KLF8 in cancers is the key 
to finding important signal pathways leading to 
KLF8 activation in cancer. It has been reported 
that KLF8 expression is regulated at both tran-
scriptional and post-translational levels. KLF8 
acts as the downstream target of FAK which, 
activated by integrin signaling, enhances cell 
proliferation, cell migration through several in-
termediate transducers such as Src and PI3K 
[13]. KLF8 expression is highly elevated in FAK 
over-expressing cells of both mouse and human 
origins [5, 14]. Integrin-mediated cell adhesion 
was also able to upregulate KLF8 expression. 
These observations gave rise to an assumption 
that KLF8 activates cyclin D1 to regulate cell 
proliferation as a downstream mediator of FAK. 
Subsequent studies demonstrated that the FAK-
dependent regulation of KLF8 is mediated by 
SP1 transcription factor which activates KLF8 
gene expression by directly binding and activat-
ing KLF8 gene promoter. The signaling from FAK 
to SP1 is mediated by PI3K-AKT and ERK MAP-
kinase pathways [15]. KLF8 promoter contains 
Figure 1. Schematic structure of KLF8 protein. KLF8 
interacts with the transcriptional co-repressor C-
terminal binding protein (CtBP) through its repres-
sion domain (RD or PVDLS motif), with the transcrip-
tional co-activators P300 and PCAF histone acetyl-
transferases through its activation domain (AD cen-
tered on Q118/Q248), with target DNA GT-box se-
quence via the three C2H2 zinc-finger (ZnF) motifs. 
KLF8 also binds to importin through its nuclear local-
ization signal sequences and PARP-1 at the ZnF re-
gion to regulate its nuclear localization. The acetyla-
tion sites and sumoylation site of KLF8 are also 
shown. 
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GT- box (CACCC) regions, consensus binding 
sites for KLF transcription factors. Indeed, KLF3 
can directly repress whereas KLF1 directly acti-
vates KLF8 gene promoter [16]. In the presence 
of these three KLF members, KLF8 transcription 
is repressed by KLF3. In this context, KLF1 also 
activates KLF3 transcription [16]. A recent study 
has identified a cross-talk between Wnt and 
KLF8 signaling to nuclear β-catenin function in 
human liver cancer cells [17]. 
 
Post-translational modifications are an essential 
mechanism for the regulation of protein expres-
sion and function. KLF8 can be modified by vari-
ous such mechanims including sumoylation, 
acetylation ubiquitylation and PARylation. KLF8 
is sumoylated by small ubiquitin like modifiers 
SUMO-1, SUMO-2, and SUMO-3, primarily by 
SUMO-1. When sumoylated at Lys67, the func-
tion of KLF8 as a transcriptional activator or 
repressor is limited. These results suggest that 
KLF8 is sumoylated when its function is not 
needed in the cell [6]. Acetylation was found to 
be another important post-translational modifi-
cation of KLF8. KLF8 is acetylated at lysine93, 
lysine95 and lysine67 by histone acetyltrans-
ferase P300 and PCAF co-activators. Acetylation 
at the Lysine93 is mediated by P300, whereas 
acetylation at the lysine67 and lysine95 is medi-
ated by both P300 and PCAF. Lysine67 is a 
common site for both sumoylation and acetyla-
tion, thus the sumoylation and acetylation at the 
lysine67 counteract each other [18]. CtBP re-
cruits E2 and E3 ligase to enhance sumoylation 
and thus it positively regulates sumoylation. 
Acetylation at lysine93 and lysine95 inhibits 
CtBP binding to KLF8 repression domain 
(86PVDLS90) and thus indirectly inhibits sumoy-
lation. Further using lysine67, lysine93, lysine 
95 mutants it was proved that acetylation at 
these sites promotes the cyclin D1 expression 
and cell cycle progression by KLF8. A balance 
between sumoylation and acetylation appears 
to be critical for KLF8 function in cellular proc-
esses [18]. KLF8 PARylation by PARP-1 is a third 
post translational modification which is required 
for its transcriptional activity and localization in 
nucleus to bind to gene promoters [12]. In the 
absence of PARP-1 function, KLF8 undergoes 
ubiquitylation and subsequent degradation pre-
sumably by proteasome in the cytoplasm [12]. 
Till date KLF8 phosphorylation has not been 
well studied although it was predicted that 
phosphorylation at Serine165 by PKC may play 
a role in the nuclear localization and cellular 
function of KLF8. Treatment with PKC inhibitor 
results in less nuclear localization of KLF8 and 
a decrease in cyclin D1 expression [8]. 
 
KLF8 functions as a dual transcription factor  
 
KLF8 was initially identified as a transcriptional 
repressor [3]. KLF8 represses gene expression 
through binding to a co-repressor CtBP to its 
PVDLS domain (aa86-90). This domain is known 
as repression domain (RD) (Figure 1) [3]. It was 
also shown that KLF8 is widely expressed in all 
human tissues. KLF8 was found to bind to 
CACCC region or GT-box region of target gene 
promoters. CtBP binding to the PVDLS domain 
of KLF8 triggers its transcriptional repression of 
beta-globin gene promoter reporter containing a 
tandem of GT-boxes. Consistently, a systematic 
screening for KLF proteins that bind and regu-
late gamma-globin gene promoter suggested 
that KLF8 is a transcriptional repressor of 
gamma-globin gene expression [19]. Interest-
ingly, mutational disruption of the PVDLS do-
main could not completely abolish KLF8 tran-
scriptional repressor activity suggesting that 
KLF8 acts as a repressor in both CtBP-
dependent and independent manners [3]. KLF8 
was then shown to be highly overexpressed in 
FAK overexpressing cells and to transcriptionally 
activate cyclin D1 gene promoter to promote 
cell cycle progression [5]. KLF8 binds directly to 
a GT-box on cyclin D1 promoter and activates its 
expression [5]. KLF8 knockdown significantly 
decreases cyclin D1 expression and the cell 
cycle progression [5]. Later it was found that 
KLF8 also activates gene expression by recruit-
ing the co-activators P300 and PCAF to its acti-
vation domain containing the core residues of 
Q118 and Q248 [7]. P300 and PCAF in turn 
acetylate the histones to activate gene pro-
moter [7]. Mutation in this KLF8 activation do-
main completely abolishes KLF8 transcriptional 
activating activity. Both transcriptional activa-
tion and repression functions of KLF8 labeled it 
as a dual transcription factor. KLF8 plays an 
important role in cell proliferation as a dual 
transcription factor by activating cyclin D1 ex-
pression [20-22]. KLF8 directly represses KLF4 
expression to activate cell proliferation [6]. 
Given the tumor suppressor role of KLF4 [23], 
repression of KLF4 by KLF8 could contribute to 
tumor progression. KLF8 directly binds to a GT-
box on E-cadherin promoter and represses its 
activity [24, 25]. E-cadherin is a marker of 
epithelial cells and a tumor suppressor [25], 
Krüppel-like factor 8 as a regulator of cancer 
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loss of its expression leads to loss of cell-cell 
contact resulting in epithelial to mesenchymal 
transition (EMT) which is a critical early step of 
cancer cell invasion and metastasis. Recently it 
was found that KLF8 directly binds to GT-box 3 
on MMP9 promoter and transcriptionally acti-
vates its expression [26]. Matrix metallopro-
teinases (MMPs) are protease enzymes which 
break down the extracellular matrix proteins 
and promote cell invasion into other tissues. 
Increase in MMP expression and catalytic activ-
ity leads to cancer cell invasion and metastasis. 
Taken together, KLF8 appears to target tumor 
suppressors for transcriptional repression and 
tumor promoting genes for transcriptional acti-
vation for an overall effect favoring tumor pro-
gression. The downregulation of E-cadherin and 
upregulation of N-cadherin, MMP 2 and 9 as 
well as integrins have also been correlated to 
the expression of KLF8, along with the other 
EMT-promoting factors including Snail, TWISTs 
and ZEBs, during the implantation stage of bo-
vine embryogenesis [27].  
 
KLF8 in cancer 
 
Since the initial descriptions of KLF8 as a regu-
lator of beta-globin and cyclin D1 transcription 
[3, 5], several reports have been followed to 
demonstrate the aberrant overexpression of 
KLF8 in various types of human cancer includ-
ing breast [24, 26, 28], ovar-
ian [15, 28], renal [28, 29], 
liver [17, 30], gastric [31] 
and brain [20-22] cancer 
(Figure 2). Various signaling 
pathways regulating KLF8 
and its target genes associ-
ated with cancer have been 
identified (Figure 3). Initial 
effort began with a study of 
the role of KLF8 in onco-
genic transformation of 
NIH3T3 cells [28]. In that 
report, tetracycline regu-
lated inducible overexpres-
sion of KLF8 caused the 
transforming phenotypes 
including loss of contact 
inhibition and serum inde-
pendent growth [28]. On the 
other hand, overexpression 
of a KLF8 inhibiting mutant 
clearly reduces the ability of 
v-Src to transform NIH3T3 
cells and KLF8 regulation of cyclin D1 expres-
sion appears to play a partial role [28]. KLF8 
directly represses the tumor suppressor gene 
KLF4 which may also contribute to the transfor-
mation [6]. Cancer cells are benign when they 
are localized in their origin. Cancer becomes 
malignant when cancer cells invade the ex-
tracellular matrix and migrate to different loca-
tions. This process is known as metastasis if the 
cell migration takes the route of blood or lymph 
circulation. EMT is a process during which 
epithelial cells are transformed into fibroblast-
like cells that are more motile and invasive [25]. 
EMT plays a critical role in tumor metastasis. On 
one hand, EMT allows a few cancer cells to dis-
sociate and migrate away from the primary tu-
mor mass. On the other hand, it renders the 
cancer cells ability to survive the circulation by 
avoiding anoikis- an apoptotic process triggered 
by cell detachment from extracellular matrix 
that kills particularly epithelial cells. Cancer cell 
migration, invasion and metastasis are the most 
malignant stages of cancer. E-cadherin and 
MMP9 are two of the most important mediators 
in these stages. During EMT E-cadherin expres-
sion is decreased and the expression of mesen-
chymal markers such as N-cadherin and 
vimentin is increased. KLF8 directly represses E
-cadherin expression and triggers subsequent 
EMT process in both canine kidney epithelial 
cell line MDCK and human mammary epithelial 
Figure 2. KLF8 regulated human cancer types. Involved KLF8 target genes of 
transcriptional activation (upward arrows) or repression (downward arrows) are 
indicated. 
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cell line MCF-10A [24]. This induction of EMT by 
KLF8 does not appear to depend upon other 
EMT inducer proteins such as Snail. KLF8 di-
rectly activates MMP9 gene promoter by binding 
to a GT-box to increase MMP9 expression and 
catalytic activity [26]. KLF8 overexpression 
leads to increased breast cell migration and 
invasiveness. KLF8 knockdown in highly metas-
tatic breast cancer cell line significantly de-
creases  the lung metastatic rate in nude 
mouse [26]. In ovarian cancer cells KLF8 trans-
duces FAK to PI3K to AKT to SP1 signaling to 
upregulate cyclin D1 expression and enhance 
the cell cycle progression [15]. The recent dis-
covery of PARP-1 binding to KLF8 in the nucleus 
in both breast and ovarian cells [12] suggests a 
potentially interesting cooperation between 
KLF8 and PARP-1 in these cancer cell types. 
Besides breast and ovarian cancer, role of KLF8 
has been identified in a few other cancer types. 
It was reported that KLF8 protein and mRNA is 
highly overexpressed in human renal cell carci-
noma (RCC) tissues compared to that in the 
adjacent non-tumorous renal tissues [29]. Si-
lencing KLF8 expression in the RCC 786-0 cells 
induces apoptosis and inhibition of invasion in 
vitro and tumor growth in nude mice [29]. In 
human hepatocellular carcinomas (HCC), the 
aberrant overexpression of KLF8 was correlated 
with the metastatic potential, post-surgical re-
currence of the HCC tumors and poor survival 
studied in more than 300 patient cases [30]. 
Using tissue microarray analysis of the patient 
specimens and several KLF8-genetically modi-
fied HCC cell lines, the study demonstrated that 
in HCC cells KLF8 promotes proliferation and 
invasion and inhibits apoptosis by inducing the 
upregulation of cyclin D1 expression, the ex-
pression switch of EMT marker genes, the acti-
vation of MMP2, the transcrip-
tional repression of caspases 3 
and 9 and activation of Bcl-xL [30]. 
Related to this study, a most re-
cent report has suggested a role of 
KLF8 in mediating Wnt to β-
catenin signaling to activate the 
transcription of c-Myc, cyclin D1 
and Axin1 and promote HCC cell 
proliferation [17]. In gastric cancer, 
the KLF8 expression was found 
highly elevated in gastric cancer 
tissues from 80 patients and in 
human gastric cancer cell lines 
compared to the adjacent nontu-
mor gastric tissue and normal gas-
tric epithelial cells [31]. KLF8 
knockdown in the cancer cells resulted in re-
duced xenografted tumor growth in nude mice 
with decreased expression of cyclin D1 and BCL
-2, the upregulation of P27 and Bax expression 
and apoptosis in the tumor cells [31]. The first 
implication of the role of KLF8 in cancer was 
from an early study in which the U-251MG hu-
man glioblastoma cells were used [14]. That 
study showed that the expression of KLF8 in the 
cells depends upon the expression and activity 
of FAK and correlated to the increase/decrease 
of cyclin D1/p27 and the cell cycle progression. 
Subsequently, a recent study demonstrated that 
the U251 glioblastoma cell growth can be in-
ducd to undergo apoptosis by knocking down 
the expression of KLF8 [22]. In the meantime, a 
group from Germany reported the positive ex-
pression of KLF8 in human gliomas of all grades 
irrespective of the proliferation rate assumed by 
Ki67 staining, and knocking down KLF8 in the 
U87-MG glioma cells dramatically inhibited the 
cell proliferation [21].  
 
In summary, studies to date have demonstrated 
a critical role of KLF8 in the regulation of a vari-
ety of cellular processes favoring tumor progres-
sion of many cancer types. While this certainly 
suggests that KLF8 could be used as a potential 
future molecular target for cancer therapy, 
many questions regarding the tumor-promoting 
or oncogenic role and mechanisms of KLF8 re-
main to be answered by additional studies using 
well-defined experimental systems such as non-
tumorigenic human cells of cancer origins and 
KLF8 genetically engineered mouse models.  
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